![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » J&J to Gain Promising Autoimmune Disease Drug in $6.5 Billion Momenta Acquisition
J&J to Gain Promising Autoimmune Disease Drug in $6.5 Billion Momenta Acquisition
![JohnsonJohnson_Logo.gif](https://www.fdanews.com/ext/resources/test/Device_Images5/JohnsonJohnson_Logo.gif?t=1626995791&width=430)
Johnson & Johnson (J&J) announced that it will acquire the autoimmune-focused biotech company Momenta Pharmaceuticals for $6.5 billion, expanding its holdings in the area of novel treatments for autoimmune diseases.
Cambridge, Mass.-based Momenta’s key drug asset is nipocalimab, which blocks molecules in the body that set off certain autoimmune conditions. Mid-stage trial results early this summer showed that the investigational drug significantly decreased symptoms of generalized myasthenia gravis, a muscle disorder.
J&J said its Janssen subsidiary will explore nipocalimab’s usefulness for other autoimmune diseases, such as maternal-fetal and neuro-inflammatory disorders.
Upcoming Events
-
21Oct